AHR and cancer: In addition to immunosuppression driven by IDO1/IL4I1/AHR axis upregulation [48, 49], our data demonstrate that, compared to the WT, mutant Δ133p53α R273H has acquired at least seven out of the ten hallmarks of cancers [44] and that it has gained oncogenic function.